EMPA-REG OUTCOME trial and Canagliflozin Cardiovascular Assessment Study: Looking beyond the obvious
Explore this paper's citation graph
Summary
A review highlights the similarities and dissimilarities in the two trial results of the Canagliflozin CV Assessment Study.
- Type
- article
- Published
- 2017-07-01
- Cited by
- 1
- References
- 13
- Access
- Open access
- OpenAlex
- https://openalex.org/W2772861200
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:79971180
Keywords
Canagliflozin, EMPA, Medicine, Clinical trial, Empagliflozin
References
- Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study.
- SGLT2-inhibitors Trigger Downstream Mechanisms That May Exert Adverse Effects Upon Bone
- Prevalence and Prognostic Impact of Subclinical Cardiovascular Disease in Individuals With the Metabolic Syndrome and Diabetes
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin.
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
- Screening for asymptomatic coronary artery disease in patients with type 2 diabetes mellitus.
- Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials
- Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
- SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System.
- Canagliflozin and cardiovascular and renal events in type 2 diabetes
- Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes
Cited by
Related papers
- Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
- Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
- Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
- Comprehensive List of DACA Drugs
- CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME
- Abstract 207: Cardiovascular Outcomes of Sodium-glucose Co-transporter 2 Inhibitors: A Meta-analysis
- Possible Mechanisms of Action of SGLT2 Inhibitors in Heart Failure
- SGLT2 inhibition and heart failure—current concepts